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Psoralen (furocumarins) plus UVA (ultraviolet A) (320–400 nm
radiation PUVA) is a widely effective therapy for psoriasis, vitiligo
and other skin diseases [1–3]. Besides, the combination of psoralen
and ultraviolet A radiation resulted to reduce keratinocyte and
lymphocyte proliferations through a decreased secretion of cyto-
kines. The same effects have been alternatively utilized for the
treatment of human lymphoma and of autoimmune diseases
through the extracorporeal photochemotherapy (ECP) [4,5].
Evidence has been provided that these photoactive compounds
can interact with cellular macromolecules and can interfere with
DNA synthesis, as reported in many cell types including ﬁbroblast,
keratinocytes, melanocytes or leukocytes [6–10].
Low doses of PUVA induced growth inhibition without affecting
cell viability [8], while higher doses also induced apoptosis [11,12].chemical Societies. Published by E
PUVA, psoralen + ultraviolet
nsulin-like growth factor; 5-
clear antigen
ellular Biology, University of
cata di Rende, Cosenza, Italy.These compounds are currently used in the treatment of psoriasis,
cutaneous T cell lymphomas and other epithelial diseases, as pre-
viously reported, while there are only few reports about the effect
of PUVA on tumoral cells.
Recently, our paper investigated the pro-apoptotic effects in-
duced by high dose of bergapten (B) (or methoxypsoralen: 5-
MOP), in the absence of UV rays, in human breast cancer cells [13].
In this study, we have examined the effectiveness of photoacti-
vated B, at low doses, on cell proliferation, utilizing three different
breast cancer cell lines (MCF-7, SKBR-3 and ZR-75). In addition, the
inﬂuence of drug treatment on the signalling molecules, which
play a critical role in the maintenance of cell survival and apopto-
sis, has been evaluated in MCF-7 cells.2. Materials and methods
2.1. Cell culture
MCF-7, SKBR-3 and ZR-75 breast cancer cells were cultured in
DMEM medium supplemented with 7.5% FCS, 1% penicillin/
streptomycin and 1% glutamine. Sub conﬂuent cell cultures,
synchronized for 24 h in DMEM without phenol red and serum
(PRF-SFM-DMEM), were used for all experiments.lsevier B.V. All rights reserved.
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All cells were seeded (100 000 cells/well) in a complete DMEM
medium in six-well plates and become attached to the bottom of
the well overnight. On the second day, the medium was changed
and shifted for 24 h with serum-free medium. At the end of this
time, the cells were treated and incubated with B (4 lM, 6 lM)
for 4 h. After this incubation the cells were irradiated for 20, 40
and 60 min with UVA (365 nm) and then stowed in the incubator
at 37 C for 20 h (one set) and for 44 h (second set). At the end of
this period the cells were counted in a haemocytometer by trypan
blue exclusion. The results were expressed as percentage of the
controls, determined by standardizing untreated cells to 100%.
2.3. Western blotting and immunoprecipitation
Cytoplasmatic and nuclear fractions, as well as total protein ex-
tracts were obtained as previously described [14]. Proteins were
resolved on an 8% sodium dodecyl sulfate–polyacrylamide gel,
transferred to a nitrocellulose membrane (Amersham Bioscience,
Milan, Italy), and probed overnight at 4 C with the antibody indi-
cated in the ﬁgure legends.
Anti-p21 waf, anti-proliferating cell nuclear antigen (PCNA),
anti-p53, anti-b-actin, anti-p85, anti-GAP-DH, anti-Lamin B, anti-
mouse IgG and Protein A/G-agarose plus were from Santa Cruz Bio-
technology. Anti-phospho-AKT (Ser 473), anti p-AKT, anti-phospho
p-Bcl2 (Ser 70), anti-caspase 9 pAbs from Cell Signaling
Technology.
2.4. Transfections
Transient transfection experiments were performed using plas-
mid pcDNA3-c-Akt encoding for AKT protein and plasmid pcDNA3
empty vector. Cells were transfected in SFM using FuGENE6
according to the manufacture’s instructions with a mixture con-
taining 0.5 lg/well of the plasmid. 24 h after the transfection the
cells were treated for 24 h with B alone or in combination with
UV at 40 min. At the end of this incubation the cells were collected
and lysed for Western blot analysis or utilized for cell counting.
2.5. Phosphatidylinositol-3-kinase activity
Phosphatidylinositol-3-kinase (PI-3K) activity associated with
p85, was assessed by standard protocol provided by the manufac-
turer of the p85 antibody (Upstate Biotechnology). Brieﬂy, cell ly-
sates of MCF-7 cells treated or untreated with B and PUVA were
immunoprecipitated with anti-p85 and with Protein A/G agarose.
The presence of PI3K activity in immunoprecipitates was deter-
mined by incubating the beads with reaction buffer containing
10 mM HEPES (pH 7.4), 10 mM MgCl2, 50 lM ATP, 20 lCi [c32-P]
ATP, and 10 lg of L-a-phosphatidylinositol-4,5-bis phosphate for
20 min at 37 C. The reactions were stopped by adding 1 M HCl.
Phospholipids were extracted with CHCl3/methanol (1:1, v/v) and
the labelled products of the kinase reaction, the PI phosphates,
then were spotted onto trans-1,2-diaminocyclohexane-N,N,N0,N0-
tetra acetic acid – treated silica gel 60 thin layer chromatography
(TLC) plates. Radioactive spots were visualized by autoradiography
[14].
2.6. RT-PCR assay
Total cellular RNA was extracted from MCF-7 cells using TRIA-
ZOL reagent (Invitrogen, Carlobad, CA). Reverse transcription was
done using RETRO script kit (AMBION, Austin, TX).
Primers sequences include: p53 forward: 50-CTT CCT GAA AAC
AAC GTT CTG TCC-30, and reverse: 50-CCA GAC CAT CGC TAT CTGAGC A-30; rRNA 36B4 forward: 50-CTCAACATCTCCCCCTTCTC-30,
and reverse: 50-CAAATCCCATATCCTCGTCC-30.
2.7. DNA ladder formation
Cellular DNA was isolated by following the procedure previ-
ously described [14]. The DNA fragments were resolved by electro-
phoresis at 75 V on 1% agarose gel impregnated with ethidium
bromide, detected by UV transillumination, and photographed.
2.8. Statistical analysis
Each data point represents the mean ± S.D. of at least four
experiments. The data were analyzed by analysis of variance using
the STATPAC computer program.3. Results
3.1. Bergapten and PUVA affect breast cancer cells survival
Firstly, we tested the effect of B and UV on MCF-7, SKBR-3 and
ZR-75 breast cancer cell proliferations. We observed that single
treatment with B after 24 h affects cell survival prevalently in
MCF-7 cells whereas more consistent effects were observed under
the combined treatment (PUVA) in all the cell lines tested. The pro-
longed treatments up to 48 hours showed the greatest antiprolifer-
ative responses in the three breast cancer cell lines (Fig. 1). Lower
doses of the drug did not induce signiﬁcant changes in all the cell
lines tested (data not shown).
Since MCF-7 cells resulted to be more responsive to psoralen
treatment, we investigated the effect of the drug and UV on the
PI-3K/AKT pathway, mainly involved in the regulation of cell sur-
vival. B alone or UVA were able to down-regulate the PI3K activity,
while their combination (5-MOP + UVA) did not further decrease
the enzymatic activity (Supplementary Fig. 1A). Besides, either B
or UV irradiation were able to down-regulate phospho-AKT levels
(Ser 473) (Supplementary Fig. 1B).
The same signalling molecule was evaluated in MCF-7 under
IGF-I (insulin-like growth factor) – cell stimulated condition, since
this growth factor represents a key nutritional element for breast
cancer cell proliferation as largely well documented [15–17]. It is
worth to observe how B, both in a single treatment and in combi-
nation with UV, is able to counteract the stimulatory effect induced
by IGF-I (100 ng/ml) on the phospho-AKT (Supplementary Fig. 1C).
3.2. Bergapten and PUVA treatments induce p53 and p21 WAF
expression in MCF-7cells
Our recent work demonstrated that B, particularly at higher
doses without UV, is able to up-regulate p53 and to transactivate
p53 gene promoter [13]. On the basis of these results we wanted
to assess whether lower doses of B in the presence of UV light
(at different time of cell exposure) can modulate p53, p21 and
phospho-Bcl-2 expression in MCF-7 cells. A representative
Western blot in Fig. 2A reveals that B at both 4 and 6 lM induces
an increased expression of p53 and p21 WAF which resulted more
up-regulated under the combined treatment: PUVA rays; however,
under B 6 lM + 60 min UV the augment is less pronounced. In this
last condition the cells are undergone to consistent stress stimuli
that might in turn affect the p53 and p21 WAF protein levels.
On the contrary, the phospho-Bcl-2 expression, a p53-linked
protein, resulted to be down-regulated and barely detectable un-
der the combined treatment B plus UV (Fig. 2A).
Since p53 is involved in the induction of apoptosis, next we
studied the expression of caspase-9 and the pattern of DNA ladder
Fig. 1. Cell viability of MCF-7, SKBR-3 and ZR-75 cells after bergapten and bergapten + UVA (PUVA) treatments. (A) MCF-7, (B) SKBR-3 and (C) ZR-75 breast cancer cells
seeded in six-well plates (100 000 cells/well) were treated for 24 and 48 h with 4 and 6 lM of bergapten or irradiated with UVA in a single schedule for 20, 40 and 60 min (0).
Half of these plates were undergone to PUVA treatment. The values are expressed as percentage of the control, determined by standardizing untreated cells to 100%. C:
control; B: bergapten. Triplicate results are expressed as mean ± S.D. (n = 4). dP < 0.05; ddP < 0.01 as compared to untreated control cells.
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est concentration used (B6 lM), induces the cleavage of caspase-9,
this event was more consistent under PUVA (B6 lM + UV 40 and
60 min) (Fig. 2B). Furthermore, as evidenced in Fig. 2C, PUVA treat-
ment resulted in the appearance of DNA ladder.
3.3. Bergapten facilitates the nuclear translocation of the p53 and up-
regulates its gene transcription
Considering that B is able to up-regulate p-53 protein levels, we
checked if the psoralen could also affect the intracellular compart-
mentalization of the protein inﬂuencing the p53 functional
activity.
As reported in the Supplementary Fig. 2A, a nuclear p53 in-
crease was induced by B 4 and 6 lM a similar effect was repro-
duced by PUVA treatment.
Subsequently, to investigate whether B may inﬂuence p53
gene transcription, we performed RT-PCR in MCF-7 treated with
the drug (6 lM) with or without UV rays given for 20 and
40 min. The results showed that B alone stimulates p53 gene tran-scription which appears more increased by PUVA (Supplementary
Fig. 2B).
3.4. p21 WAF protein co-immunoprecipitates with PCNA in MCF-7
cells following PUVA. The overexpression of AKT rescues cell survival
We carried out immunoprecipitation experiments to determine
whether the PUVA-induced p21 WAF might serve to recruit the
PCNA, a key factor necessary for DNA polymerase d function.
Endogenous p21 WAF protein from MCF-7 cells was immuno-
precipitated with anti-p21 WAF antibody and then it was probed
with anti-PCNA antibody (Fig. 3A). Only PUVA treatment in MCF-
7 cells leads to an increased co-association between p21 and PCNA
with respect to controls, thus resulting in inhibition of DNA repli-
cation (Fig. 3A).
Therefore, we investigated if the transient over-expression of
pro-survival p-AKT protein in MCF-7 cells might affect the degree
of co-association of PCNA with p21 WAF (Fig. 3B).
To this aim, we transiently transfected MCF-7 cells with plas-
mid vector pcDNA3-c-AKT encoding for the AKT protein and then
Fig. 2. Bergapten up-regulates the expression of p53, p21, p-Bcl2 while PUVA induces apoptotic events. (A) MCF-7 cells were treated for 24 h with bergapten (B) alone and
UVA as indicated in terms of minutes. (B) Western blot analysis of caspase-9 in MCF-7 cells treated for 24 h with bergapten (B) and UVA as indicated. b-Actin was used as
loading control. Results are representative of three independent experiments. (C) DNA ladder in MCF-7 cells. M: DNA marker; C: control.
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In MCF-7 cells over expressing p-AKT, as conﬁrmed by total pAKT
levels, both p21 and PCNA did not associate, while only a weak
band was observed in PUVA–treated MCF-7 cells (Fig. 3B). In cells
over expressing p-AKT, the levels of p21 in the immunoprecipi-
tated samples were lower than those ones observed in MCF-7 cells.
In agreement with these last data, in MCF-7 cells the over
expression of AKT protein is able to better recover cell proliferation
in the presence of drug treatment compared to the results shown
in Fig. 1 and obtained in MCF-7 wild type cells (Fig. 3C). Similar
data were observed in the other breast cancer cells (data not
shown).4. Discussion
In this study, the effect of B, alone and in combination with UV
light, has been examined on the cellular growth of breast tumoral
cells.
Our data have demonstrated that treatment of MCF-7, SKBR-3
and ZR-75 breast cancer cells with B and, in a higher extent, with
PUVA, has determined a lowering of cell proliferation.The best effect has been obtained in MCF-7 cells, responsive
also to the single drug treatment. This epithelial breast cancer de-
rived MCF-7 cell line is one of the most frequent model systems
used, and the best representative hormone-dependent trans-
formed phenotype.
The effectiveness of the psoralen compounds has been attrib-
uted to their DNA photobinding properties, thereby preventing cel-
lular division [6–10].
The B treatment affects the PI3K/AKT survival signal in MCF-7
cells and, furthermore, the same results were established in IGF-I
– stimulated cells, where the drug was also active in antagonizing
the up-regulatory effect of this growth factor on phospho-AKT pro-
tein. The PUVA treatment, in this last experimental condition, does
not give any additional effect. The last data acquire particular rel-
evance considering previous ﬁndings which demonstrated the cru-
cial role of IGF-I and/or estradiol in maintaining breast cancer cell
growth by inﬂuencing the PI3K pathways [15–17].
On the other hand, B has elicited an enhanced expression of p53
mRNA and protein content and it has also enhanced the p53 nucle-
ar localization. In this sub-cellular compartment p53 acts as a fac-
tor involved in transcriptional regulation of two well known p53
target genes with opposite functions like Bcl-2 and PTEN [18,19].
Fig. 3. Different expression of p21-PCNA complex in MCF-7 wild type and MCF-7
cells over expressing AKT protein, treated with bergapten and PUVA. Inﬂuence on
cell proliferation. Cellular extracts were prepared from MCF-7 cells (A) and MCF-7
cells transient transfected with plasmid pcDNA3-c-Akt encoding for AKT protein
(B), treated for 24 h with bergapten (B) and UVA as shown. Immunoprecipitation
assay was performed using anti-p21 waf antibody. Immunoprecipitated proteins
were resolved and subjected to immunoblotting with anti-PCNA antibody and anti-
p21 waf. Prior the immunoprecipitation experiment an aliquot of the lysate
corresponding to 20 lg of protein was loaded to determined total pAKT levels in
MCF-7 wild type and MCF-7 cells overexpressing p-AKT. C: untreated control cells;
C Empty vector: untreated cells transfected with plasmid pcDNA3 empty vector.
Results are representative of three independent experiments. (C) MCF-7 cells
transient transfected with plasmid pcDNA3-c-Akt encoding for AKT protein were
subject to bergapten and bergapten + UV (40 min) treatment for 24 h. The values
are expressed as percentage of the control, determined by standardizing untreated
cells to 100%. C: control; B: bergapten. Triplicate results are expressed as
mean ± S.D. (n = 3).
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expression of p53, obtained in MCF-7 cells under B treatment, well
ﬁt with previous ﬁndings concerning the direct binding of the
oncosoppressor protein to the negative responsive-element pres-
ent in the promoter region of Bcl-2 gene [18]. The down-regulation
of Bcl-2 may result in an increase of apoptosis, as we observed un-
der PUVA treatments, and it is consistent with the cleavage of cas-
pase-9.
In addition, the main feature of apoptosis in MCF-7 cells, under-
gone to PUVA treatment, has been the formation of 180–200-bp
segments, which resulted from the double-stranded nucleosomal
DNA fragmentation. These data emphasize how low doses of the
photoactivated product have remarkable effects on tumoral cell
proliferation and on apoptotic signals. Whereas, in the absence ofUV light, higher doses of the drug are necessary to reproduce anal-
ogous effects, as documented in our previous paper [13].
The low phospho-AKT levels, induced by the treatment, affect
the MCF-7 cell survival. Under this condition, p21, associated with
PCNA, produced MCF-7 cell proliferation arrest. On the contrary,
this event was completely abrogated when we induced AKT pro-
tein over expression. Indeed, MCF-7 cells over expressing AKT were
less responsive to psoralen and UV, with respect to MCF-7 wild
type. In the ﬁrst cell line reported, the release of PCNA from com-
plex with p21 contributed to maintain DNA replication.
In conclusion, we have found that psoralen, and in a higher ex-
tent the photoactivated molecule, can signiﬁcantly affect breast
cancer cell proliferations. Furthermore, a dual action of psoralen
was observed in MCF-7 cells: B is able to signiﬁcantly reduce the
p-AKT survival signalling, while the photoactivated B induced
apoptosis, as revealed by the increase of p53, caspase activation
and DNA ladder.
Our studies suggest that B alone, or as a photoactivated product,
could be used as an active molecule able to counteract effectively
the survival and growth of breast hormone-responsive tumors.Acknowledgments
We thank Dr. Andrew R.O. Watson .The Scripps Research Insti-
tute of La Jolla, CA, for providing pcDNA3-c-Akt plasmid; Prof A.
Martire for English revision.
This work was supported by A.I.R.C. grant 2007 and Calpark
grant 2002.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.04.001.
References
[1] Parrish, J.A., Fitzpatrick, T.B., Tanenbaum, L. and Pathak, M.A. (1974)
Photochemotherapy of psoriasis with oral methoxalen and longwave
ultraviolet light. N. Engl. J. Med. 291, 1207–1211.
[2] Honig, B., Morison, W.L. and Karp, D. (1994) Photochemotherapy beyond
psoriasis. J. Am. Acad. Dermatol. 31, 775–790.
[3] Luftl, M., Degitz, K., Plewig, G. and Rocken, R. (1997) Psoralen bath plus UV-A
therapy-possibilities and limitations. Arch. Dermatol. 133, 1597–1603.
[4] Balogh, A., Merkel, U., Looks, A., Vollandt, R. and Wollina, U. (1998) Drug
monitoring of orally administered 8-methoxypsoralen in patients treated with
extracorporeal photopheresis. Skin Pharmacol. Appl. Skin Phyisiol. 11, 258–
265.
[5] Plumas, J., Drillat, P., Jacob, M.C., Richard, M.J. and Favrot, M.C. (2003)
Extracorporeal photochemotherapy for treatment of clonal T cell
proliferations. Bull. Cancer 90, 763–770.
[6] Baden, H.P., Parrington, J.M., Delhanty, J.D. and Pathak, M.A. (1972) DNA
synthesis in normal and xeroderma pigmentosum ﬁbroblasts following
treatment with 8-methoxypsoralen and long wave ultraviolet light. Biochim.
Biophys. Acta. 262, 247–255.
[7] Tokura, Y., Edelson, R.L. and Gasparro, F.P. (1991) Formation and removal of 8-
MOP-DNA photoadducts in keratinocytes: effects of calcium concentration
and retinoids. J. Invest. Dermatol. 96, 942–949.
[8] Kao, C.H. and Yu, H.S. (1992) Comparison of the effect of 8-methoxypsoralen
(8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and
in vitro. J. Invest. Dermatol. 98, 734–740.
[9] Scherer, R., Kern, B. and Braun-Falco, O. (1997) The human peripheral
lymphocyte – a model system for studying the combined effect of psoralen
plus black light. Klin. Wochenschr. 55, 137–140.
[10] Morison, W.L. (1981) Photoimmunologic effects of psoralens and UVA. Proc.
Int. Psoralens SIR Pergamon Press 3, 15–325.
[11] Marks, D.I. and Fox, R.M. (1991) Mechanism of photochemotherapy – induced
apoptotic cell death in lymphoid cells. Biochem. Cell. Biol. 69, 754–760.
[12] Yoo, E.K., Rook, A.H., Elenitsas, R., Gasparro, F.P. and Vowels, B.R. (1996)
Apoptosis induction of ultraviolet light A and photochemotherapy in
cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action.
J. Invest. Dermatol. 107, 235–242.
[13] Panno, M.L., Giordano, F., Palma, M.G., Bartella, V., Rago, V., Maggiolini, M.,
Sisci, D., Lanzino, M., De Amicis, F. and Andò, S. (2009) Evidence that
bergapten, independently of its photoactivation, enhances p53 gene
2326 M.L. Panno et al. / FEBS Letters 584 (2010) 2321–2326expression and induces apoptosis in human breast cancer cells. Curr. Cancer
Drug Targets 4, 469–481.
[14] Panno, M.L., Giordano, F., Mastroianni, F., Morelli, C., Brunelli, E., Palma, M.G.,
Pellegrino, M., Aquila, S., Miglietta, A., Mauro, L., Bonoﬁglio, D. and Andò, S.
(2006) Evidence that low doses of Taxol enhance the functional
transactivatory properties of p53 on p21 waf promoter in MCF-7 breast
cancer cells. FEBS Lett. 580, 2371–2380.
[15] Surmacz, E., Guvakova, M.A., Nolan, M.K., Nicosia, R.F. and Sciacca, L. (1998)
Type I insulin-like growth factor receptor function in breast cancer. Breast
Cancer Res. Treat. 3, 255–267.[16] Arteaga, C.L. (1992) Interference of the IGF system as a strategy to inhibit
breast cancer growth. Breast Cancer Res. Treat. 22, 101–106.
[17] Lee, A.V. and Yee, D. (1995) Insulin-like growth factors and breast cancer.
Biomed. Pharmacother. 49, 415–421.
[18] Miyashita, T., Harigai, M., Hanada, M. and Reed, J.C. (1994) Identiﬁcation of a
p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54,
3131–3135.
[19] Mayo, L.D. and Donner, D.B. (2002) The PTEN, Mdm2, p53 tumor suppressor-
oncoprotein network. Trends Biochem. Sci. 27, 462–467.
